129973-51-9

Basic information

• Product Name: 2,2-Difluoro-2-phenyl-ethanol
• Synonyms: 2,2-Difluoro-2-phenyl-ethanol;β,β-difluoro- Benzeneethanol
• CAS NO: 129973-51-9
• Molecular Formula: C8H8F2O
• Molecular Weight: 158.148
• Mol File: 129973-51-9.mol

Chemical Properties

• CAS DataBase Reference: 2,2-Difluoro-2-phenyl-ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-Difluoro-2-phenyl-ethanol(129973-51-9)
• EPA Substance Registry System: 2,2-Difluoro-2-phenyl-ethanol(129973-51-9)

Safety Data

• Hazardous Substances Data: 129973-51-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2,2-Difluoro-2-phenyl-ethanol is used as a reagent in organic synthesis for its ability to participate in a variety of chemical reactions, facilitating the creation of complex organic molecules.
Used as a Building Block in Pharmaceutical Synthesis:
In the pharmaceutical industry, 2,2-Difluoro-2-phenyl-ethanol is used as a building block for the synthesis of pharmaceutical compounds, owing to its unique structural features that can be incorporated into medicinally relevant molecules.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
2,2-Difluoro-2-phenyl-ethanol is utilized as a chiral auxiliary in asymmetric synthetic transformations, playing a crucial role in the production of enantiomerically pure compounds, which are essential in many pharmaceutical applications.
Used in Perfume and Fragrance Production:
DFPE is used as a component in the production of perfumes and fragrances, capitalizing on its ability to contribute distinct scents and improve the overall quality of these products.
Used as a Flavoring Agent in the Food Industry:
In the food industry, 2,2-Difluoro-2-phenyl-ethanol is used as a flavoring agent to enhance the taste and aroma of various food products, providing a unique flavor profile.
It is important to handle 2,2-Difluoro-2-phenyl-ethanol with care, as it is considered to be toxic and may cause irritation upon contact with skin or eyes. Proper safety measures should be taken during its use in any application.

Upstream product

• 2248-46-6 ethyl 2,2-difluoro-2-phenylacetate 
• 591-50-4 iodobenzene 
• 122-78-1 phenylacetaldehyde 
• 129660-35-1 α,α-difluoro-α-phenylacetaldehyde 
• 13344-76-8 α-fluorobenzeneacetaldehyde 
• 360-03-2 2,2-Difluoro-2-phenylacetic acid 
• 103-80-0 phenylacetyl chloride 
• 56071-96-6 methyl 2,2-difluoro-2-phenylacetate 
• 129973-38-2 2,2-Difluoro-2-phenylethyl phenyl sulfide 
• 108661-89-8 2-Bromo-1,1-difluoro-1-phenylethane 
• 1786-36-3 (2-bromo-1-fluoroethyl)benzene 
• 696-31-1 α-fluorostyrene 
• 233280-91-6 2-acetoxy-1,1-difluoro-1-phenylethane 
• 129973-45-1 2,2-Difluoro-2-phenyl-1-(phenylthio)ethyl acetate 

Downstream Products

• 129660-35-1 α,α-difluoro-α-phenylacetaldehyde 
• 144156-71-8 Ethyl 3,3-difluoro-2-hydroxy-3-phenylpropanoate 
• 762292-90-0 2-amino-3,3-difluoro-3-phenylpropionic acid 
• 762292-95-5 3,3-difluoro-2-hydroxy-3-phenylpropionic acid 
• 476415-67-5 trifluoromethanesulfonic acid 2,2-difluoro-2-phenyl-ethyl ester 
• 915132-91-1 N-benzyl-6-(2,2-difluoro-(2-phenyl)ethoxy)hexane-1-amine 
• 1562526-18-4 2-(2,2-difluoro-2-phenylethyl)-6-hydroxy-1,2,4-triazine-3,5(2H,4H)-dione 
• 1562526-19-5 4-(benzyloxymethyl)-6-bromo-2-(2,2-difluoro-2-phenylethyl)-1,2,4-triazine-3,5(2H,4H)-dione 
• 1357257-17-0 benzyloxycarbonyl-[(1R)-1-(phenyldifluoromethyl)allyl]amine 
• 1357257-39-6 N-(4-bromophenyl)sulfonyl-[(1R)-1-(phenyldifluoromethyl)allyl]amine 
• 1357257-16-9 (S)-tert-butylsulfinyl-[(1S)-1-(phenyldifluoromethyl)allyl]amine 
• 1357257-15-8 (R)-tert-butylsulfinyl-[(1R)-1-(phenyldifluoromethyl)allyl]amine 
• 1361944-79-7 N-[1-ethoxy-2-phenyl-2,2-difluoroethyl]-(R)-tert-butylsulfinamide 

Relevant articles and documents

Synthesis of the Lipophilic Amine Tail of Abediterol Enabled by Multiphase Flow Transformations

The development of a continuous-flow sequence for the synthesis of an important drug candidate precursor is reported. Abediterol is a β2-adrenoceptor agonist that has undergone phase IIa clinical trials for the treatment of respiratory disease. A flow seq

Optimization and sustainability assessment of a continuous flow Ru-catalyzed ester hydrogenation for an important precursor of a β2-adrenergic receptor agonist

The development of a ruthenium-catalyzed continuous flow ester hydrogenation using hydrogen (H2) gas is reported. The reaction was utilized for the reduction of an important precursor in the synthesis of abediterol, a β2-adrenoceptor agonist that has undergone phase IIa clinical trials for the treatment of asthma and chronic obstructive pulmonary disorder. The reaction was investigated within a batch autoclave by using a design of experiments (DoE) approach to identify important parameter effects. The optimized flow process was successfully operated over 6 h with inline benchtop19F NMR spectroscopy for reaction monitoring. The protocol is shown to be high yielding (98% yield, 3.7 g h?1) with very low catalyst loading (0.065 mol%). The environmental impact of the Ru-catalyzed hydrogenation was assessed and compared to an existing stoichiometric lithium aluminum hydride (LAH) reduction and sodium borohydride (NaBH4) reduction. The process mass intensity (PMI) for the Ru-catalyzed hydrogenation (14) compared favorably to a LAH reduction (52) and NaBH4reduction (133).

Diaminodiphosphine tetradentate ligand and ruthenium complex thereof, and preparation methods and applications of ligand and complex

The invention discloses a diaminodiphosphine tetradentate ligand and a ruthenium complex thereof, and preparation methods and applications of the ligand and the complex, and provides a ruthenium complex represented by a formula I, wherein L is a diaminodiphosphine tetradentate ligand represented by a formula II, and X and Y are respectively and independently chlorine ion, bromine ion, iodine ion,hydrogen negative ion or BH4. According to the present invention, the ruthenium complex exhibits excellent catalytic activity in the catalytic hydrogenation reactions of ester compounds, has high yield and high chemical selectivity, is compatible with conjugated and non-conjugated carbon-carbon double bond, carbon-carbon triple bond, epoxy, halogen, carbonyl and other functional groups, and hasgreat application prospects.

An alternative synthesis of the lipophilic tail portion of abediterol using linear-selective hydroformylation

Abediterol is a compound currently in development for the treatment of respiratory disease at AstraZeneca. In this work we employ hydroformylation, an under-utilised reaction in the synthesis of pharmaceutical intermediates, as a key step to access the li

Lewis acid-mediated defluorinative [3+2] cycloaddition/aromatization cascade of 2,2-difluoroethanol systems with nitriles

The properties of C?F bonds, including high thermal and chemical stability, make derivatization of organic fluorine-containing compounds by the activation of the C?F bond and subsequent functionalization quite challenging. We herein report a Lewis acid-mediated defluorinative cycloaddition/aromatization cascade of 2,2-difluoroethanols with nitriles as a novel synthetic method for the preparation of 2,4,5-trisubstituted oxazoles. This reaction, which involves cleavage of two C?F bonds and the consecutive formation of C?O and C?N bonds in a one-pot fashion, features a broad substrate scope and moderate to high reaction yields. Mechanistic studies revealed that the reaction is initiated by the Lewis acid-mediated ring closure of the 2,2-difluoroethanol to produce the fluoroepoxide intermediate. (Figure presented.).

Triazolopyridine ethers as potent, orally active mGlu2positive allosteric modulators for treating schizophrenia

Triazolopyridine ethers with mGlu2positive allosteric modulator (PAM) activity are disclosed. The synthesis, in vitro activity, and metabolic stability data for a series of analogs is provided. The effort resulted in the discovery of a potent, selective, and brain penetrant lead molecule BMT-133218 ((+)-7m). After oral administration at 10 mg/kg, BMT-133218 demonstrated full reversal of PCP-stimulated locomotor activity and prevented MK-801-induced working memory deficits in separate mouse models. Also, reversal of impairments in executive function were observed in rat set-shifting studies at 3 and 10 mg/kg (p.o.). Extensive plasma protein binding as the result of high lipophilicity likely limited activity at lower doses. Optimized triazolopyridine ethers offer utility as mGlu2PAMs for the treatment of schizophrenia and merit further preclinical investigation.

Benzoxazine compound and its preparation methods and application

The invention relates to a benzoxazine compound represented in the following formula 1. The benzoxazine compound can serve as a beta 2 receptor agonist. The formula can be seen from the description.

Preparation of difluorinated alcohol compound

The present invention relates to a method for producing a difluoro alcohol compound. According to the present invention, compared to prior arts, the method for producing the difluoro alcohol compound is simple, safe, and cost-competitive in terms of a use of reagents, since a synthesis is simply carried out via a reaction between N-fluorobenzenesulfonimide and aldehyde in the presence of L-proline. Accordingly, the method of the present invention can be effectively applied to the production of the difluoro alcohol which gives a wide range of applications such as functional drugs, pesticides, and raw materials for polymeric compounds.COPYRIGHT KIPO 2017

A simple primary amine catalyst for enantioselective α-hydroxylations and α-fluorinations of branched aldehydes

A new primary amine catalyst for the asymmetric α-hydroxylation and α-fluorination of α-branched aldehydes is described. The products of the title transformations are generated in excellent yields with high enantioselectivities. Both processes can be performed within short reaction times and on gram scale. The similarity in results obtained in both reactions, combined with computational evidence, implies a common basis for stereoinduction and the possibility of a general catalytic mechanism for α-functionalizations. Promising initial results in α-amination and α-chlorination reactions support this hypothesis.

TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.